We gratefully acknowledge the contributions from our sponsors:

First International Workshop on Epigenetic Cancer Therapy

German Cancer Research Center
Heidelberg, Germany
Organizers: Frank Lyko and Olaf Witt

June 17-19, 2010
Thursday, June 17

18:00  Welcome Buffet at Haus Buhl
19:00  Guided tour through the Old Town and Heidelberg Castle with a wine reception on the Castle Terraces

Friday, June 18

09:00  Opening remarks:
       Frank Lyko and Olaf Witt
09:00-09:45  Keynote lecture
            Peter A. Jones: The Cancer Epigenome and Epigenetic Therapy
09:45-10:45  Session I DNMT Inhibitors
              chair: Jean-Pierre Issa
            Victor Marquez (Frederick, USA):
              The coreography between DNA and histone methylation in cancer.
            Marit Liland Sandvolt (Clavis Pharma, Oslo, Norway):
              Lipid vector modification of azacytidine
10:45-11:15  Coffee Break
11:15-12:45  Session II DNMT Inhibitors
              chair: Jean-Pierre Issa
            Kyle MacBeth (Celgene, San Francisco, USA)
              DNMT-Inhibitors and beyond - additional mechanisms and targets
            Carsten Müller-Tidow (Münster, Germany)
              Aberrant DNA methylation in AML pathogenesis and treatment resistance
            Jean-Pierre Issa (Houston, USA)
              Screening for synergies with DNMT inhibitors

13:00-14:00  Lunch

14:00-15:30  Session I HDAC Inhibitors
              chair: Saverio Minucci
            Sriram Balasubramanian (Pharmacyclics, Sunnyvale, USA)
              Development of selective HDAC inhibitors
            Pamela Munster (San Francisco, USA)
              Epigenetic modulation of estrogen receptor signaling (preclinical and clinical)
            Lucia Altucci (Naples, Italy)
              Novel options for multiple epigenetic targeting against cancer
15:30-16:00  Coffee Break
16:00-17:30  Session II HDAC Inhibitors
              chair: Saverio Minucci
            Nick La Thangue (Oxford, UK)
              Biomarkers for HDAC inhibitors
            David Schrump (Bethesda, USA)
              Epigenetic strategies for lung cancer therapy
            Peter Atadja (Novartis, Shanghai, China)
              The HDAC Inhibitor LBH589 (Panobinostat) in anti-cancer therapy

Saturday, June 19

09:00-10:30  Session I Biomarkers
              chair: Christoph Plass
            Christoph Plass (Heidelberg, Germany)
              Epigenetic alterations in cancer genomes
            Bob Brown (London, UK)
              Epigenetic biomarkers in ovarian cancer therapy
            Neli Ulrich (Heidelberg, Germany)
              One-carbon metabolism and beyond: environment and epigenetics
10:30-11:00  Coffee Break
11:00-12:30  Session II Biomarkers
              chair: Christoph Plass
            Michael Haberland (Dallas, USA)
              Using mouse genetics to elucidate HDACi targets
            Saverio Minucci (Milan, Italy)
              Epigenetic alterations in leukemogenesis
            Ricky Johnstone (Melbourne, Australia)
              Rational use of epigenetic therapies for the treatment of cancer
12:30       Closing remarks
12:30-13:30  Lunch and farewell